Steap3 Protein Measurement for Red Blood Cell Storage Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective quality control measures for red blood cell (RBC) units prior to transfusion, leading to variability in post-transfusion survival and potential toxicity, which can result in adverse clinical outcomes for recipients.
Innovation Solution
Measuring the levels of the Steap3 protein in RBC samples to predict post-transfusion survival and toxicity, with higher activity indicating lower storage quality or suitability for transfusion, allowing for pre-transfusion assessment and donor suitability evaluation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current quality control measures (pathogen testing, compatibility testing, storage history monitoring) are used, then pathogen safety and basic transfusion safety are ensured, but post-transfusion survival variability and toxicity cannot be predicted
Solution Approach 1:
The patent applies preliminary action by measuring Steap3 protein levels in RBC units before transfusion to predict post-transfusion survival and toxicity. This pre-transfusion assessment allows identification of units with poor storage quality or high toxicity risk before they are administered to patients, enabling proactive selection of suitable units.
Solution Approach 2:
The patent uses Steap3 protein as an intermediary marker to indirectly assess RBC storage quality and predict transfusion outcomes. Instead of directly measuring complex storage parameters or clinical outcomes, the Steap3 protein level serves as a measurable proxy that correlates with post-transfusion survival and toxicity, simplifying the prediction process.
2Duration of action of stationary object
If RBC units are stored for extended periods to maintain supply, then availability is improved, but storage quality deteriorates and toxicity increases
Solution Approach 1:
The patent implements feedback by measuring Steap3 protein levels in stored RBC units to monitor storage quality in real-time. This feedback mechanism allows identification of units that have deteriorated during storage, enabling selective use of fresh units and avoidance of toxic stored units, thus optimizing the balance between supply availability and safety.
Solution Approach 2:
The patent applies preliminary action by assessing Steap3 levels before transfusion to predict which stored units remain safe for use. This allows the blood bank to strategically select and transfuse units with acceptable storage quality, extending the usable life of stored blood while avoiding units that have developed significant toxicity.
3Reliability
If Steap3 protein level measurement is implemented, then post-transfusion survival and toxicity can be predicted, but measurement complexity and resource requirements increase
Solution Approach 1:
The patent uses Steap3 protein as an intermediary marker to simplify the assessment of RBC storage quality. By measuring this single protein level, the system avoids the complexity of measuring multiple storage parameters, clinical outcomes, or conducting extensive donor history reviews, thereby reducing measurement system complexity while maintaining predictive accuracy.
Solution Approach 2:
The patent applies parameter changes by focusing on a specific measurable property (Steap3 protein level) that correlates with transfusion outcomes. This single-parameter approach simplifies the measurement system compared to multi-parameter or clinical-based assessment methods, making the system more feasible for routine blood bank operation.
4Object-affected harmful factors
If individual RBC unit quality is assessed, then patient safety is improved, but transfusion logistics and unit selection become more complex
Solution Approach 1:
The patent applies preliminary action by measuring Steap3 levels in RBC units before they are assigned to patients. This pre-assessment creates a database of unit quality metrics that can be quickly retrieved and used during transfusion decisions, simplifying the unit selection process compared to real-time complex evaluation during patient care.
Solution Approach 2:
The patent implements feedback by establishing a system where Steap3 measurements provide immediate information about unit quality that feeds back into transfusion decision-making. This feedback loop enables blood bank staff to quickly identify and select safe units, making the process more efficient rather than more complex.
Data Source
AI summary
Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.